Golden State Equity Partners Cardiff Oncology, Inc. Transaction History
Golden State Equity Partners
- $602 Million
- Q4 2025
A detailed history of Golden State Equity Partners transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Golden State Equity Partners holds 24,500 shares of CRDF stock, worth $52,675. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,500Holding current value
$52,675% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
21.9MCall Options Held
475KPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA3.72MShares$8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.65 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY2.47MShares$5.3 Million0.09% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$4.76 Million0.01% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.96MShares$4.22 Million2.05% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $93.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...